CAMBRIDGE, Mass., Aug. 5 /PRNewswire/ -- Radius Health (“Radius”) today announced topline Phase 2 data demonstrating that in women with osteoporosis, BA058 -- the company’s novel PTHrP (parathyroid hormone-related protein) analog -- significantly increased bone mineral density (BMD) at the lumbar spine and femoral neck (a common fracture site located in the hip joint) after six months of therapy. The gains in lumbar spine and femoral neck BMD were further increased in a subset of patients that elected to continue therapy for a total of 12 months of treatment, and at both time points, the changes were greater than those seen with Forteo(R) (teriparatide), the reference drug used in this dose-finding study.
